scholarly journals Dopaminergic Medication-Related Repetitive Behaviors in Parkinson’s Disease

2008 ◽  
Vol 1 (2) ◽  
pp. 101-103 ◽  
Author(s):  
Jong Sam Baik ◽  
Sang Won Han ◽  
Jeong Yeon Kim ◽  
Jae Hyeon Park
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Repetitive Behaviors ◽  
Dopaminergic Medication

scholarly journals Implications of dopaminergic medication withdrawal in Parkinson’s disease

2021 ◽  
Author(s):  
J. Koschel ◽  
K. Ray Chaudhuri ◽  
L. Tönges ◽  
M. Thiel ◽  
V. Raeder ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Medication ◽  
Medication Withdrawal

scholarly journals Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective

2021 ◽  
pp. 1-6
Author(s):  
Mark Tomishima ◽  
Agnete Kirkeby
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Clinical Trials ◽  
Phase I Clinical Trials ◽  
Preclinical Models ◽  
Preclinical Development ◽  
Dopaminergic Medication ◽  
Gene Therapies ◽  
Advanced Therapies ◽  
New Phase

After many years of preclinical development, cell and gene therapies have advanced from research tools in the lab to clinical-grade products for patients, and today they constitute more than a quarter of all new Phase I clinical trials for Parkinson’s disease. Whereas efficacy has been convincingly proven for many of these products in preclinical models, the field is now entering a new phase where the functionality and safety of these products will need to stand the test in clinical trials. If successful, these new products can have the potential to provide patients with a one-time administered treatment which may alleviate them from daily symptomatic dopaminergic medication.

scholarly journals Influence of Dopaminergic Medication on Conditioned Pain Modulation in Parkinson's Disease Patients

PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0135287 ◽  
Author(s):  
Wiebke Grashorn ◽  
Odette Schunke ◽  
Carsten Buhmann ◽  
Katarina Forkmann ◽  
Sabrina Diedrich ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Pain Modulation ◽  
Conditioned Pain Modulation ◽  
Dopaminergic Medication

scholarly journals Lung Function Testing On and Off Dopaminergic Medication in Parkinson's Disease Patients With and Without Dysphagia

2015 ◽  
Vol 3 (2) ◽  
pp. 146-150 ◽  
Author(s):  
Tareq Sawan ◽  
Mary Louise Harris ◽  
Christopher Kobylecki ◽  
Laura Baijens ◽  
Michel van Hooren ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Lung Function ◽  
Lung Function Testing ◽  
Dopaminergic Medication ◽  
Function Testing

scholarly journals Differential dopaminergic modulation of spontaneous cortico-subthalamic activity in Parkinson’s disease

2020 ◽  
Author(s):  
Abhinav Sharma ◽  
Diego Vidaurre ◽  
Jan Vesper ◽  
Alfons Schnitzler ◽  
Esther Florin
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Beta Activity ◽  
Beta Band ◽  
Time Resolved ◽  
Functional Roles ◽  
Dopaminergic Medication ◽  
Physiological Processes ◽  
Motor Network ◽  
Theta Frequency

AbstractPathological oscillations including elevated beta activity in the subthalamic nucleus (STN) and between STN and cortical areas are a hallmark of neural activity in Parkinson’s disease (PD). Oscillations also play an important role in normal physiological processes and serve distinct functional roles at different points in time. We characterised the effect of dopaminergic medication on oscillatory whole-brain networks in PD in a time-resolved manner by employing a hidden Markov model on combined STN local field potentials and magnetoencephalography (MEG) recordings from 17 PD patients. Dopaminergic medication led to communication within the medial and orbitofrontal cortex in the delta/theta frequency range. This is in line with deteriorated frontal executive functioning as a side effect of dopamine treatment in Parkinson’s disease. In addition, dopamine caused the beta band activity to switch from an STN-mediated motor network to a frontoparietal-mediated one. In contrast, dopamine did not modify locally-originating STN oscillations in PD. STN–STN synchrony emerged both on and off medication. By providing electrophysiological evidence for the differential effects of dopaminergic medication on the discovered networks, our findings open further avenues for electrical and pharmacological interventions in PD.

scholarly journals A survey into the influence of dopaminergic drug exposure on ‘sense of presence’ symptoms in patients with parkinson's disease

BJPsych Open ◽  
2021 ◽  
Vol 7 (S1) ◽  
pp. S279-S280
Author(s):  
Emma Padfield ◽  
Hannah Potticary ◽  
Tim Segal
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Regression Analysis ◽  
Drug Exposure ◽  
Drug Dosage ◽  
Equivalent Dose ◽  
Dopaminergic Medication ◽  
Dopaminergic Drug ◽  
Sense Of Presence ◽  
The Relationship

AimsThe first objective was to estimate prevalence of sense of presence (SoP) experiences in patients with Parkinson's Disease (PD), including whether onset was prior to or after commencing dopaminergic medication. The second objective was to explore the relationship between frequency of SoP experiences and dopaminergic drug, drug dosage and length of drug exposure. The experimental hypothesis was that SoP symptoms in PD would present more frequently in patients treated longer and with higher dopaminergic drug doses.BackgroundPD is a debilitating neurodegenerative disorder. Psychiatric symptoms are common and associated with impaired quality of life and higher treatment costs. PD psychosis often starts with ‘minor hallucinations’, the most common being a false ‘sense of presence’ (SoP), the vivid sensation that someone else is nearby when nobody is there. SoP symptoms typically do not cause significant distress but may act as a prognostic marker for future severe psychosis and may prompt alteration of treatment or reduction in dopaminergic drug dosage. This study aimed to extend prior research by characterizing SoP further and investigating the link with dopaminergic medication.MethodThis was a retrospective, cross-sectional study. Twenty-one patients diagnosed with PD completed a questionnaire to identify presence of SoP symptoms, duration of symptoms, timing of onset related to dopaminergic treatment and the frequency of symptoms in relation to current levodopa equivalent dose (LED). Descriptive frequencies were compared using a two-tailed t-test. Multiple regression analysis was conducted to assess the relationship between frequency of SP experiences, levodopa equivalent dose and length of drug exposure.ResultSixteen of twenty-one patients reported experiencing SoP symptoms. Patients who had not experienced SoP symptoms had a significantly lower LED than those who had experienced these symptoms. There were no other significant differences between the groups. No statistical significance was shown on regression analysis; however our study was not adequately powered for the regression analysis as the number of participants was too low.ConclusionThis study confirms that SoP symptoms are common among patients with PD and supports a correlation between the total daily equivalent dose of levodopa and SoP symptoms. It does not provide evidence for a temporal relationship between onset of SoP symptoms and duration of dopaminergic treatment. The study was insufficiently powered and a larger study is required to investigate further.

The reach-to-grasp movement in Parkinson’s disease before and after dopaminergic medication

2000 ◽  
Vol 38 (1) ◽  
pp. 46-59 ◽  
Author(s):  
U. Castiello ◽  
K.M.B. Bennett ◽  
C. Bonfiglioli ◽  
R.F. Peppard
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Reach To Grasp ◽  
Dopaminergic Medication ◽  
Before And After

scholarly journals Levodopa-Responsive Primary Slow Orthostatic Tremor: A Premotor Sign of Parkinson’s Disease?

2020 ◽  
Vol 12 (1) ◽  
pp. 1-6
Author(s):  
Fumihito Yoshii ◽  
Wakoh Takahashi ◽  
Koji Aono
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Surface Electromyography ◽  
Specific Binding ◽  
Low Frequency ◽  
Orthostatic Tremor ◽  
Specific Binding Ratio ◽  
Dopaminergic Medication ◽  
Neurological Signs ◽  
Dat Spect

We present a case of primary orthostatic tremor (OT) responsive to dopaminergic medication. The patient was a 62-year-old woman, who had leg tremor on standing for 2 years. No parkinsonian or other neurological signs were observed. Surface electromyography of the quadriceps muscles showed regular 5–6 Hz muscle discharges. [123I]-FP-CIT DAT-SPECT imaging revealed decreased specific binding ratio values in the striatum compared with age-matched controls. Her leg tremor almost completely disappeared following administration of levodopa 200 mg and pramipexole 0.75 mg. Since her OT with low-frequency discharge was responsive to dopaminergic medication, we speculate that it may be a premotor sign of Parkinson’s disease.

scholarly journals Preserved Serotonergic Activity in Early-Onset Parkinson’s Disease

2019 ◽  
Vol 47 (3) ◽  
pp. 344-349 ◽  
Author(s):  
Hee Kyung Park ◽  
Jae-Jung Lee ◽  
Young-Min Park
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Early Onset ◽  
Auditory Evoked Potentials ◽  
Late Onset ◽  
Post Treatment ◽  
Dopaminergic Medication ◽  
Serotonergic Activity ◽  
The Absolute ◽  
Onset Group

ABSTRACT:Background:Serotonergic dysfunction may play an important role in motor and nonmotor symptoms of Parkinson’s disease (PD). The loudness dependence of auditory evoked potentials (LDAEP) has been used to evaluate serotonergic activity. Therefore, this study aimed to determine central serotonergic activity using LDAEP in de novo PD according to the age at onset and changes in serotonergic activity after dopaminergic treatment.Methods:A total of 30 patients with unmedicated PD, 16 in the early-onset and 14 in the late-onset groups, were enrolled. All subjects underwent comprehensive neurological examination, laboratory tests, the Unified Parkinson’s Disease Rating Scale, and LDAEP. The LDAEP was calculated as the slope of the two N1/P2 peaks measured at the Cz electrode, first at baseline conditions (pretreatment) and a second time after 12 weeks (post-treatment) following dopaminergic medications.Results:The absolute values of pretreatment N1/P2 LDAEP (early-onset: late-onset, 0.99 ± 0.68: 1.62 ± 0.88, p = 0.035) and post-treatment N1 LDAEP (early-onset: late-onset, −0.61 ± 0.61: −1.26 ± 0.91, p = 0.03) were significantly lower in the early-onset group compared with those of the late-onset group. In addition, a higher value of pretreatment N1/P2 LDAEP was significantly correlated with the late-onset group (coefficient = 1.204, p = 0.044). The absolute value of the N1 LDAEP decreased after 12 weeks of taking dopaminergic medication (pretreatment: post-treatment, −1.457 ± 1.078: −0.904 ± 0.812, p = 0.0018).Conclusions:Based on the results of this study, LDAEP could be a marker for serotonergic neurotransmission in PD. Central serotonergic activity assessed by LDAEP may be more preserved in early-onset PD patients and can be altered with dopaminergic medication.

Sign in / Sign up

Export Citation Format

Share Document